Dr. Diede is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
351 N. Sumneytown Pike
Mailstop UG4D-58
North Wales, PA 19454- Is this information wrong?
Education & Training
- University of WashingtonFellowship, Pediatric Hematology/Oncology, 2005 - 2008
- University of WashingtonResidency, Pediatrics, 2004 - 2005
- University of WashingtonInternship, Pediatrics, 2003 - 2004
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2003
- University of ChicagoPhD, Pathology, 2001
- University of ChicagoBA, Chemistry, 1988 - 1992
Certifications & Licensure
- PA State Medical License 2014 - 2016
- WA State Medical License 2005 - 2015
Awards, Honors, & Recognition
- Young Investigator Award Alex's Lemonade Stand for Childhood Cancer Research, 2010
- Scholar St. Baldrick's Foundation, 2010
- Basic Research Fellowship in memory of Emily Ann Dorfman American Brain Tumor Association, 2010
- Join now to see all
Clinical Trials
- Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) Start of enrollment: 2011 Mar 04
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) Start of enrollment: 2012 Nov 20
- Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) Start of enrollment: 2013 Aug 28
- Join now to see all
Publications & Presentations
PubMed
- 53 citationsRandomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.Jason A Chesney, Antoni Ribas, Georgina V Long, John M Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F Gajewski, Ralf Gutzmer, Piotr Rutkowski, Le...> ;Journal of Clinical Oncology. 2023 Jan 20
- 34 citationsPhase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhi...Ana Arance, Luis de la Cruz-Merino, Teresa M Petrella, Rahima Jamal, Lars Ny, Ana Carneiro, Alfonso Berrocal, Ivan Márquez-Rodas, Anna Spreafico, Victoria Atkinson, Fe...> ;Journal of Clinical Oncology. 2023 Jan 1
- 2 citationsBurden and Risk Factors of Brain Metastases in Melanoma: A Systematic Literature Review.Xiang-Lin Tan, Amy Le, Huilin Tang, Madeline Brown, Emilie Scherrer, Jiali Han, Ruixuan Jiang, Scott J Diede, Irene M Shui> ;Cancers. 2022 Dec 12
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: